Pfizer Inc (PFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pfizer Inc (PFE) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($835.00 Million) by net assets ($85.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Pfizer Inc for the company's overall valuation and market capitalisation.
Pfizer Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pfizer Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency. Explore how high is Pfizer Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Western Digital Corporation
NASDAQ:WDC
|
0.124x |
|
The Boeing Company
NYSE:BA
|
-0.030x |
|
Shopify Inc
TO:SHOP
|
0.052x |
|
Eaton Corporation PLC
NYSE:ETN
|
0.056x |
|
Danaher Corporation
NYSE:DHR
|
0.033x |
|
Banco Santander S.A
F:BSDK
|
0.080x |
|
Pfizer Inc
SA:PFIZ34
|
0.010x |
|
Novo Nordisk A/S
CO:NOVO-B
|
0.039x |
Annual Cash Flow Conversion Efficiency for Pfizer Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 1989 to 2025. View current stock price of Pfizer Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.78 Billion | $11.71 Billion | 0.135x | -6.33% |
| 2024-12-31 | $88.50 Billion | $12.74 Billion | 0.144x | +47.79% |
| 2023-12-31 | $89.29 Billion | $8.70 Billion | 0.097x | -68.07% |
| 2022-12-31 | $95.92 Billion | $29.27 Billion | 0.305x | -27.45% |
| 2021-12-31 | $77.46 Billion | $32.58 Billion | 0.421x | +85.35% |
| 2020-12-31 | $63.47 Billion | $14.40 Billion | 0.227x | +14.37% |
| 2019-12-31 | $63.45 Billion | $12.59 Billion | 0.198x | -20.07% |
| 2018-12-31 | $63.76 Billion | $15.83 Billion | 0.248x | +8.00% |
| 2017-12-31 | $71.66 Billion | $16.47 Billion | 0.230x | -13.50% |
| 2016-12-31 | $59.84 Billion | $15.90 Billion | 0.266x | +19.02% |
| 2015-12-31 | $65.00 Billion | $14.51 Billion | 0.223x | -5.28% |
| 2014-12-31 | $71.62 Billion | $16.88 Billion | 0.236x | +1.67% |
| 2013-12-31 | $76.62 Billion | $17.77 Billion | 0.232x | +11.05% |
| 2012-12-31 | $81.68 Billion | $17.05 Billion | 0.209x | -14.77% |
| 2011-12-31 | $82.62 Billion | $20.24 Billion | 0.245x | +88.78% |
| 2010-12-31 | $88.27 Billion | $11.45 Billion | 0.130x | -29.24% |
| 2009-12-31 | $90.45 Billion | $16.59 Billion | 0.183x | -41.94% |
| 2008-12-31 | $57.74 Billion | $18.24 Billion | 0.316x | +54.05% |
| 2007-12-31 | $65.12 Billion | $13.35 Billion | 0.205x | -17.58% |
| 2006-12-31 | $70.72 Billion | $17.59 Billion | 0.249x | +12.05% |
| 2005-12-31 | $66.36 Billion | $14.73 Billion | 0.222x | -6.40% |
| 2004-12-31 | $68.88 Billion | $16.34 Billion | 0.237x | +32.11% |
| 2003-12-31 | $65.38 Billion | $11.74 Billion | 0.180x | -64.82% |
| 2002-12-31 | $19.95 Billion | $10.18 Billion | 0.510x | +0.80% |
| 2001-12-31 | $18.29 Billion | $9.26 Billion | 0.506x | +31.40% |
| 2000-12-31 | $16.08 Billion | $6.20 Billion | 0.385x | -60.25% |
| 1999-12-31 | $3.15 Billion | $3.06 Billion | 0.970x | +191.62% |
| 1998-12-31 | $8.81 Billion | $2.93 Billion | 0.332x | +68.95% |
| 1997-12-31 | $8.28 Billion | $1.63 Billion | 0.197x | -33.32% |
| 1996-12-31 | $7.00 Billion | $2.07 Billion | 0.295x | -10.02% |
| 1995-12-31 | $5.55 Billion | $1.82 Billion | 0.328x | -3.87% |
| 1994-12-31 | $4.36 Billion | $1.49 Billion | 0.341x | +5.48% |
| 1993-12-31 | $3.90 Billion | $1.26 Billion | 0.323x | +90.52% |
| 1992-12-31 | $4.75 Billion | $807.00 Million | 0.170x | +1.36% |
| 1991-12-31 | $5.06 Billion | $847.60 Million | 0.167x | -0.33% |
| 1990-12-31 | $5.12 Billion | $860.50 Million | 0.168x | +16.84% |
| 1989-12-31 | $4.56 Billion | $655.80 Million | 0.144x | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more